The global transcatheter pulmonary valve replacement (TPVR) market is experiencing significant growth, driven by the increasing prevalence of congenital heart diseases (CHDs), which affect approximately 1 in 100 live births worldwide. In the U.S., 40,000 babies are born with CHDs each year, with about 25% requiring early medical interventions to manage the condition. As the global population ages, there is a rise in valve degeneration cases, further emphasizing the need for effective treatments. TPVR procedures, which offer a minimally invasive alternative to traditional open-heart surgeries, are gaining popularity due to their ability to reduce risks, shorten recovery times, and improve patient outcomes. These advancements in less invasive options are expanding the adoption of TPVR, positioning it as a preferred solution for treating both congenital and age-related heart valve conditions.
